



Universiteit  
Leiden  
The Netherlands

## Quantitative systems pharmacology modeling of biotherapeutics in oncology

Betts, A.M.

### Citation

Betts, A. M. (2021, June 3). *Quantitative systems pharmacology modeling of biotherapeutics in oncology*. Retrieved from <https://hdl.handle.net/1887/3176516>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3176516>

**Note:** To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/3176516> holds various files of this Leiden University dissertation.

**Author:** Betts, A.M.

**Title:** Quantitative systems pharmacology modeling of biotherapeutics in oncology

**Issue date:** 2021-06-03

# **Quantitative systems pharmacology modeling of biotherapeutics in oncology**

Alison M. Betts

Cover design: Edgar Stewart Design & Illustration, Concord MA 01742

Printing: Alpha Graphics, Concord MA, U.S.A

© Copyright, Alison Mary Betts, 2021.

ISBN: 978-0-578-89120-0

All rights reserved. No part of this thesis may be reproduced in any form or by any means without permission of the author

# **Quantitative systems pharmacology modeling of biotherapeutics in oncology**

## **Proefschrift**

Ter verkrijging van de graad van Doctor aan de Universiteit Leiden,  
op gezag van Rector Magnificus prof. dr. ir. H. Bijl,  
volgens besluit van het College voor Promoties  
te verdedigen op 3 juni 2021  
klokke 15:00 uur

Door

Alison Mary Betts  
Geboren te Edinburgh, Scotland  
Op 4 juli 1972

**Promotores:**

Prof. dr. P.H. van der Graaf

Prof. dr. J. Burggraaf

**Promotiecommissie:**

Prof. dr. H. Irth, voorzitter

Prof. dr. J.A. Bouwstra, secretaris

Prof. dr. C. Kloft, University of Berlin

Prof. dr. J.P. Balthasar, University at Buffalo, The State University of New York

Prof. dr. A.D.R. Huitema, Netherlands Cancer Institute

Dr. J.G.C. van Hasselt

The research described in this thesis was performed at Pfizer Worldwide Research & Development, Groton CT, and Cambridge MA, USA.  
Publication of this thesis was financially supported by Pfizer, Inc. and Applied BioMath, LLC, Concord MA 01742.

## Table of contents

|                    |                                                                                                                                                                                                                                                              |     |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| <b>SECTION I</b>   | <b>INTRODUCTION TO TRANSLATIONAL MODELING IN ONCOLOGY</b>                                                                                                                                                                                                    |     |
| Chapter 1          | Thesis introduction and scope                                                                                                                                                                                                                                | 7   |
| <b>SECTION II</b>  | <b>MODELING OF MONOCLONAL ANTIBODIES</b>                                                                                                                                                                                                                     |     |
| Chapter 2          | Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets:<br>A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach | 15  |
| <b>SECTION III</b> | <b>MODELING OF ANTIBODY DRUG CONJUGATES</b>                                                                                                                                                                                                                  |     |
| Chapter 3          | Establishing in vitro–in vivo correlation for antibody drug conjugate efficacy: a PK/PD modeling approach                                                                                                                                                    | 46  |
| Chapter 4          | Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1                                                                                                                     | 71  |
| Chapter 5          | Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: A Retrospective Analysis of Inotuzumab Ozogamicin                                                                                                                      | 98  |
| <b>SECTION IV</b>  | <b>MODELING OF BISPECIFIC ANTIBODIES</b>                                                                                                                                                                                                                     |     |
| Chapter 6          | A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART®                                                                                      | 125 |
| Chapter 7          | Mechanistic quantitative pharmacology strategies for the early clinical development of bispecific antibodies in oncology                                                                                                                                     | 158 |
| <b>SECTION V</b>   | <b>SUMMARY, DISCUSSION, AND CONCLUSION</b>                                                                                                                                                                                                                   |     |
| Chapter 8          | Summary, discussion, and conclusion                                                                                                                                                                                                                          | 186 |
| Chapter 9          | Nederlandse samenvatting                                                                                                                                                                                                                                     | 197 |
| <b>SECTION VI</b>  | <b>APPENDICES</b>                                                                                                                                                                                                                                            |     |
|                    | Curriculum vitae and list of publications                                                                                                                                                                                                                    | 211 |
|                    | Affiliations of authors                                                                                                                                                                                                                                      | 216 |
|                    | Acknowledgements                                                                                                                                                                                                                                             | 218 |